Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30841994 | 0.83 | EGLN2 (0.33) | DYRK1ADYRK1BDYRK2EGLN2TLR8 | |
| SCHEMBL30841993 | 0.78 | CYP2A6 (0.45) | EGLN2TLR8DRD2DRD4DRD3 | |
| SCHEMBL31664024 | 0.75 | CYP11B2 (0.46) | EGLN2CLK4KDM4E | |
| SCHEMBL30842043 | 0.75 | DRD2 (0.42) | EGLN2TLR8DRD2DRD4DRD3 | |
| SCHEMBL30505931 | 0.72 | TLR8 (0.41) | DYRK1AEGLN2TLR8IDO1 | |
| SCHEMBL31030490 | 0.71 | HPGD (0.42) | TLR8KDM4E | |
| SCHEMBL31596040 | 0.69 | DRD2 (0.37) | DRD2DRD4DRD3CYP2A6ERN1 | |
| SCHEMBL29935937 | 0.69 | PIK3CA (0.41) | TLR8DRD2DRD4DRD3ERN1 | |
| SCHEMBL30842096 | 0.69 | HRH3 (0.40) | DYRK1ADYRK1BEGLN2JAK2RET | |
| SCHEMBL670862 | 0.69 | CYP3A4 (0.34) | DYRK1ADYRK1BDYRK2KDRCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4588914-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| CN-120019043-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119264042-A | Cyclopentane derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024078620-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NPR1, CBR1, NAT1 | DYRK1A 3829/4885DYRK1B 4211/4885DYRK2 3874/4885 |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | WEE1, WEE2, NOS1 | DYRK1A 4696/4885DYRK1B 4693/4885DYRK2 4314/4885 |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, NOS1 | DYRK1A 4696/4885DYRK1B 4693/4885DYRK2 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.